Intravenous (IV) solutions sit at an odd intersection in healthcare: they are among the most basic, unglamorous products in medicine — bags of saline, dextrose, and electrolytes — yet they are also one of the most fragile links in the hospital supply chain, and increasingly, a fixture of the consumer wellness world. Recent years have exposed both sides of that story.

Despite these disruptions, the category continues to expand. Grand View Research projects the worldwide intravenous solutions will climb to roughly $28.7 billion by 2033, with North America out in front of every other region, commanding close to 42% of global revenue as of 2025. That regional dominance lines up closely with where the supply chain vulnerabilities described below have been most acutely felt.

A Supply Chain Built on Thin Margins

The clearest lesson of the last two years has come from crisis rather than growth charts. When Hurricane Helene flooded a Baxter International plant in North Cove, North Carolina, in late 2024, the country got a rude reminder of just how concentrated IV fluid production really is. That single facility supplied roughly 60% of the nation's IV fluids. In the aftermath, a survey by group-purchasing organization Premier Inc. found more than 86% of healthcare providers experiencing shortages, and over half had ten days or fewer of inventory left. Hospitals postponed elective surgeries, rationed supplies, and leaned on paramedic-started IV lines rather than starting fresh bags.

This wasn't an isolated event. Saline solution has been on the FDA's shortage list since 2018, sterile water since 2021, and various dextrose concentrations since 2022 — well before any hurricane. A similar shock hit in 2017, when Hurricane Maria damaged Baxter's Puerto Rico plants. The pattern points to a structural issue rather than bad luck: sterile fluid manufacturing has high regulatory barriers to entry and low profit margins, so manufacturers have little financial incentive to build in spare capacity. As one American Hospital Association official put it, this is a shortage nobody can simply stockpile their way out of.

The policy response has been significant. The Department of Health and Human Services invoked the Defense Production Act to help Baxter secure materials, and the FDA authorized temporary shelf-life extensions so usable product wouldn't go to waste. Baxter airlifted supply from overseas plants, and rival manufacturer B. Braun Medical helped fill gaps — at one point moving more than 60 truckloads of product out of a Florida facility ahead of another storm.

For hospitals, the experience left a mark. Some administrators say it's permanently changed how they think about hydration — favoring oral rehydration with water or electrolyte drinks over automatic IV use where clinically appropriate, partly for resilience and partly to cut down on medical waste.

Two Very Different Sales Channels

What makes IV solutions an interesting category to watch is that they now move through two almost entirely separate commercial pathways: the traditional clinical supply chain, and a fast-growing direct-to-consumer wellness market.

The Clinical Channel: Wholesalers, GPOs, and Specialty Distribution

In hospitals, IV fluids typically follow what's known as "traditional" or "mainline" distribution. Rather than ordering from dozens of manufacturers individually, hospital pharmacies buy through full-line pharmaceutical wholesalers — the largest being McKesson, Cencora, and Cardinal Health — who hold the required pharmacy licenses and simplify procurement into a single relationship. Group purchasing organizations (GPOs) like Premier layer on top of this, negotiating collective pricing and contracts for their hospital members.

For higher-cost, more sensitive products, such as blood-derived items or biologics, a separate specialty distribution track exists, with tighter inventory control and dedicated business units (McKesson Plasma and Biologics, Cardinal's SPD, and independent players like FFF and Prodigy). Bulk and wholesale suppliers also serve clinics, surgery centers, and smaller practices directly, offering saline, dextrose, and lactated solutions at volume discounts.

During the 2024–25 shortage, this channel showed both its strength and its weakness: wholesalers and GPOs gave hospitals a fast way to coordinate conservation and allocation strategies, but the concentration of manufacturing meant there was little room to substitute suppliers when one plant went offline.

The Consumer Channel: Drip Bars, Mobile Nurses, and Apps

Running in parallel — and largely disconnected from hospital procurement — is the rise of IV therapy as a wellness product. Storefront "drip bars," concierge med spas, and mobile IV services now market hydration, vitamin, and recovery infusions directly to consumers, positioning them alongside services like cryotherapy and IM injections.

The mobile model in particular has taken off: licensed nurses travel to a client's home, office, hotel, or event and administer a customized IV blend for hydration, energy, immune support, or hangover recovery, often booked through an app or website in the same way someone might book a car ride. Physical wellness clinics still capture the largest share of this market, but mobile providers are the fastest-growing segment, benefiting from integration with digital booking platforms and appeal to busy professionals, athletes, and travelers.

Marketing for this channel looks nothing like traditional pharmaceutical sales. Providers compete on local SEO, Google Maps visibility, review counts, and social media presence on platforms like Instagram and TikTok, treating IV therapy more like a lifestyle service than a medical product — even though it's still administered by licensed clinicians under medical oversight.

Where the Two Worlds Might Intersect

For now, hospital-grade fluid manufacturing and consumer IV wellness are supplied through very different mechanisms — one running through wholesalers and GPOs bound by pharmacy licensing, the other through direct booking and retail-style marketing. But they draw on the same underlying raw materials and, in some cases, the same manufacturers' broader supply base. A future disruption in bulk fluid or bag manufacturing could just as easily ripple into the wellness channel as it did into hospitals in 2024.

The bigger long-term story may be less about market size and more about resilience and diversification: onshoring production, reducing dependence on single facilities, and building conservation practices into routine clinical decision-making — regardless of which channel the fluid ultimately moves through.